Clinical evaluation of cisplatin sensitivity of germline polymorphisms in neoadjuvant chemotherapy for urothelial cancer Journal Article

   

Authors:	O'Donnell, P. H.; Alanee, S.; Stratton, K. L.; Garcia-Grossman, I. R.; Cao, H.; Ostrovnaya, I.; Plimack, E. R.; Manschreck, C.; Ganshert, C.; Smith, N. D.; Steinberg, G. D.; Vijai, J.; Offit, K.; Stadler, W. M.; Bajorin, D. F.
Article Title:	Clinical evaluation of cisplatin sensitivity of germline polymorphisms in neoadjuvant chemotherapy for urothelial cancer
Abstract:	Micro-Abstract To identify patients with urothelial cancer most likely to benefit from neoadjuvant chemotherapy, we evaluated germline pharmacogenomic markers for an association with response in 205 patients across 3 institutions. Stage pT0 (26%) and < pT2 (50%) rates were consistent across the respective discovery and replication cohorts. Despite the large effects for 3 polymorphisms in the discovery set, none were associated with achievement of pT0 or < pT2 on replication. Multi-institutional efforts are feasible and will be necessary to achieve advances in urothelial cancer precision medicine. © 2016 Elsevier Inc.
Keywords:	bladder cancer; pharmacogenomics; precision medicine; treatment response prediction
Journal Title:	Clinical Genitourinary Cancer
Volume:	14
Issue:	6
ISSN:	1558-7673
Publisher:	Elsevier Inc.
Date Published:	2016-12-01
Start Page:	511
End Page:	517
Language:	English
DOI:	10.1016/j.clgc.2016.03.006
PROVIDER:	scopus
PMCID:	PMC5018246
PUBMED:	27150640
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-84963517143&partnerID=40&md5=10277a34cb73acedf2e92290e6887a8e
Notes:	Article -- Export Date: 6 December 2016 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/101481